Vir Biotechnology Astellas Deal Puts VIR-5500 And Valuation In Focus [Yahoo! Finance]
Vir Biotechnology, Inc. (VIR)
Company Research
Source: Yahoo! Finance
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Vir Biotechnology (NasdaqGS:VIR) announced a global collaboration with Astellas Pharma to develop and commercialize VIR-5500 for metastatic castration-resistant prostate cancer. The agreement includes substantial upfront and near-term funding to support VIR-5500 and broader pipeline development. Positive Phase 1 data for VIR-5500 reported promising anti-tumor activity and safety in prostate cancer patients. The deal marks Vir's entry into high-profile immuno-oncology partnerships and highlights its PRO-XTEN dual-masking T-cell engager technology. Vir Biotechnology, known for its focus on infectious diseases, is now stepping further into immuno-oncology with Astellas alongside VIR-5500. For investors watching biotech, this move connects Vir with a large pharma partner at a time when targeted cancer therapies and T-cell engagers are drawing sustained industry att
Show less
Read more
Impact Snapshot
Event Time:
VIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIR alerts
High impacting Vir Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
VIR
News
- Vir Biotechnology (VIR) had its price target raised by HC Wainwright from $15.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Vir Biotechnology to Participate in Upcoming Investor ConferencesBusiness Wire
- Vir Biotechnology (VIR) had its "outperform" rating reaffirmed by Leerink Partners.MarketBeat
- Vir Biotechnology Announces Pricing of Public Offering of Common Stock [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology Announces Pricing of Public Offering of Common StockBusiness Wire
VIR
Earnings
- 2/23/26 - Beat
VIR
Sec Filings
- 3/3/26 - Form SCHEDULE
- 3/3/26 - Form 4
- 3/2/26 - Form 144
- VIR's page on the SEC website